The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology annual meeting May 29 to June 2 at McCormick Place in Chicago. The event, recognized as the world's largest clinical cancer research gathering, draws more than 45,000 participants each year, including clinicians, scientists, and patient advocates.
Five presentations from Roswell Park faculty and fellows are highlighted for this year's meeting. Eunice Wang, MD, Chief of Leukemia at Roswell Park, will give an invited opening-day presentation on Ziftomenib and Revumenib for Relapsed or Refractory Acute Myeloid Leukemia. Her talk is part of the New Drugs in Oncology: Incorporation into Practice educational session scheduled for Friday, May 29. Dr. Wang will discuss recently FDA-approved agents for AML with a particular gene mutation—NPM1 alteration—providing details about safe dosage, potential adverse events, and management strategies. FDA approval of ziftomenib was based on results from a clinical trial co-led by Dr. Wang.
Five Roswell Park Fellows will receive 2026 ASCO Annual Meeting Merit Awards presented by Conquer Cancer, the ASCO Foundation. The honorees are Vaishali Deenadayalan, MBBS; Yu Fujiwara, MD; Fayaz Aijaz Ahmed Khan, MBBS; Jayasree Krishnan, MBBS; and Zunairah Shah, MBBS—all trainees who are first authors on abstracts chosen for presentation at the meeting.
Additional featured research includes Michael Wong, MD, PhD, FRPC's rapid oral abstract titled "A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial" (Abstract 9518), which he will present on Saturday afternoon.
Vaishali Deenadayalan is also presenting as first author on "Impact of protein–energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis" (Abstract 1135). Thoracic surgeon Todd Demmy will participate onsite in the U.S. National Science Foundation's Innovation Corps program during ASCO 2026.
